Top

Published in:

Open Access 01-12-2021 | Fatty Liver | Research article

Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis

Authors: Nader Salari, Niloufar Darvishi, Kamran Mansouri, Hooman Ghasemi, Melika Hosseinian-Far, Fateme Darvishi, Masoud Mohammadi

Published in: BMC Endocrine Disorders | Issue 1/2021

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is a common disorder that is known to be the leading cause of chronic liver disease worldwide. This study aims to systematically review and meta-analyze the association between PNPLA3 rs738409 polymorphism and non-alcoholic fatty liver.

Methods

Following a systematic review and meta-analysis method, articles without any time limitation, were extracted from SID, MagIran, IranDoc, Scopus, Embase, Web of Science (WoS), PubMed and ScienceDirect international databases. Random effects model was used for analysis, and heterogeneity of studies was investigated considering the I² index and using Comprehensive Meta-Analysis software.

Results

The odds ratio of CC genotype in patients with non-alcoholic fatty liver demonstrates the protective effect of CC genotype with the ratio of 0.52, whereas CG genotype presents an increasing effect of CG genotype with the ratio of 0.19, and GG genotype also showed an increasing effect of GG genotype with the ratio of 1.05. Moreover, CG + GG genotypes as a single group demostrated an odds rartio of 0.88.

Conclusion

This meta-analysis highlights that people with CC genotype has 52% lower chance of developing non-alcoholic fatty liver disease, and those with CG genotype had 19% higher risk of developing non-alcoholic fatty liver. Those with GG genotype were 105% more likely to develop non-alcoholic fatty liver than others. Moreover, those present in a population with CG + GG genotypes were 88% more likely to have non-alcoholic fatty liver disease.

Song GH, et al. Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population. Medicine. 2016;95(33):e4569.

Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, et al. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol. 2018;53(3):438–48. https://doi.org/10.1007/s00535-017-1372-8.CrossRefPubMed

Tan HL, Zain SM, Mohamed R, Rampal S, Chin KF, Basu RC, et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol. 2014;49(6):1056–64. https://doi.org/10.1007/s00535-013-0850-x.CrossRefPubMed

Xia MF, Lin HD, Chen LY, Wu L, Ma H, Li Q, et al. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes. Diabetologia. 2019;62(4):644–54. https://doi.org/10.1007/s00125-018-4805-x.CrossRefPubMed

Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol (Australia). 2015;30(5):821–9. https://doi.org/10.1111/jgh.12889.CrossRef

Xia MF, Chen LY, Wu L, Ma H, Li Q, Aleteng Q, et al. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng study. Aliment Pharmacol Ther. 2019;50(6):684–95. https://doi.org/10.1111/apt.15372.CrossRefPubMed

Zain SM, Mohamed R, Mahadeva S, Cheah PL, Rampal S, Basu RC, et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet. 2012;131(7):1145–52. https://doi.org/10.1007/s00439-012-1141-y.CrossRefPubMedPubMedCentral

Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surg Obes Relat Dis. 2015;11(4):888–94. https://doi.org/10.1016/j.soard.2014.07.016.CrossRefPubMed

Marzuillo P, Grandone A, Perrone L, Miraglia del Giudice E. Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: the role of genetics. World J Hepatol. 2015;7(11):1439–43. https://doi.org/10.4254/wjh.v7.i11.1439.CrossRefPubMedPubMedCentral

10.

Yamamoto K, Kogiso T, Taniai M, Hashimoto E, Tokushige K. Differences in the genetic backgrounds of patients with alcoholic liver disease and non-alcoholic fatty liver disease. Jgh Open. 2019;3(1):17–24. https://doi.org/10.1002/jgh3.12097.CrossRefPubMed

11.

Wang JZ, Cao HX, Chen JN, Pan Q. PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases. 2018;6(8):167–75. https://doi.org/10.12998/wjcc.v6.i8.167.CrossRefPubMedPubMedCentral

12.

Yuan S, Liu H, Yuan D, Xu J, Chen Y, Xu X, et al. PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells. J Cell Mol Med. 2020;24(2):1541–52. https://doi.org/10.1111/jcmm.14839.CrossRefPubMed

13.

Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract. 2016;2016:1–13. https://doi.org/10.1155/2016/2862173.CrossRef

14.

Xu R, et al. Association between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: a HuGE Review and Meta-Analysis. Scientific Reports. 2015;5:9284.

15.

Xu M, Li Y, Zhang S, Wang X, Shen J, Zhang S. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in Northeast China. Ann Hepatol. 2019;18(3):456–60. https://doi.org/10.1016/j.aohep.2018.10.005.CrossRefPubMed

16.

Xia MF, Ling Y, Bian H, Lin HD, Yan HM, Chang XX, et al. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment Pharmacol Ther. 2016;43(5):631–42. https://doi.org/10.1111/apt.13521.CrossRefPubMed

17.

Wang S, Song J, Shang X, Chawla N, Yang Y, Meng X, et al. Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population. Bmc Medical Genetics. 2016;17(1):90. https://doi.org/10.1186/s12881-016-0352-9.CrossRefPubMedPubMedCentral

18.

Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, et al. The PNPLA3 I148M polymorphismis associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int. 2011;31(v9):1326–31. https://doi.org/10.1111/j.1478-3231.2011.02526.x.CrossRefPubMed

19.

Choobini N, Azarpira N, Mashayekhi MR. Association of PNPLA3 gene polymorphism (rs738409) and nonalcoholic fatty liver disease in southern Iranian population. JFUMS. 2016;6(1):60–8.

20.

Salameh H, Hanayneh MA, Masadeh M, Naseemuddin M, Matin T, Erwin A, et al. PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease Spectrum. J Clin Transl Hepatol. 2016;4(3):175–91. https://doi.org/10.14218/JCTH.2016.00009.CrossRefPubMedPubMedCentral

21.

Alam S, Islam MS, Islam S, Mustafa G, Saleh AA, Ahmad N. Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver. Indian J Gastroenterol. 2017;36(5):366–72. https://doi.org/10.1007/s12664-017-0784-y.CrossRefPubMed

22.

Baclig MO, Lozano-Kühne JP, Mapua CA, Gopez-Cervantes J, Natividad FF, St Luke’s Liver Diseases Study Group. Genetic variation I148M in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos. Int J Clin Exp Med. 2014;7(8):2129–36.PubMedPubMedCentral

23.

Bhatt SP, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MAQ. Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2013;11(5):329–35. https://doi.org/10.1089/met.2012.0064.CrossRefPubMed

24.

Chen LZ, et al. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China. Lipids in Health and Disease. 2019;18(1):45.

25.

Di Costanzo A, et al. Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy. Sci Rep. 2018;8(1):3702. https://doi.org/10.1038/s41598-018-21939-0.CrossRefPubMedPubMedCentral

26.

Gorden A, Yang R, Yerges-Armstrong LM, Ryan KA, Speliotes E, Borecki IB, et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum Hered. 2013;75(1):34–43. https://doi.org/10.1159/000346195.CrossRefPubMed

27.

Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. Bmc Medical Genetics. 2010;11(1). https://doi.org/10.1186/1471-2350-11-172.

28.

Hudert CA, Selinski S, Rudolph B, Bläker H, Loddenkemper C, Thielhorn R, et al. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease. Liver Int. 2019;39(3):540–56. https://doi.org/10.1111/liv.14006.CrossRefPubMed

29.

Karoli R, et al. Association of genetic non-alcoholic fatty liver disease with insulin resistance-are we different? J Assoc Physicians India. 2019;67(March):34–8.PubMed

30.

Kawaguchi T, et al. Genetic Polymorphisms of the Human PNPLA3 Gene Are Strongly Associated with Severity of Non-Alcoholic Fatty Liver Disease in Japanese. PLoS One. 2012;7(6):e38322.

31.

Krishnasamy N, et al. Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. J Gene Med. 2020;22(4):e3160.

32.

Lee SS, Byoun YS, Jeong SH, Woo BH, Jang ES, Kim JW, et al. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci. 2014;59(12):2967–74. https://doi.org/10.1007/s10620-014-3279-z.CrossRefPubMed

33.

Li YL, et al. Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population. Bmc Medical Genetics. 2012;13(1). https://doi.org/10.1186/1471-2350-13-113.

34.

Liu WY, Zheng KI, Pan XY, Ma HL, Zhu PW, Wu XX, Rios RS, Targher G, Byrne CD, Wang XD, Chen YP, Zheng MH. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35(6):1057-64.

35.

Niriella MA, Pathmeswaran A, de Silva ST, Kasturiratna A, Perera R, Subasinghe CE, et al. Incidence and risk factors for non-alcoholic fatty liver disease: a 7-year follow-up study among urban, adult Sri Lankans. Liver Int. 2017;37(11):1715–22. https://doi.org/10.1111/liv.13478.CrossRefPubMed

36.

Niu TH, Jiang M, Xin YN, Jiang XJ, Lin ZH, Xuan SY. Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population vs. World J Gastroenterol. 2014;20(13):3655–62. https://doi.org/10.3748/wjg.v20.i13.3655.CrossRefPubMedPubMedCentral

37.

Oniki K, et al. Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects. PloS one. 2015;10(7):e0132640.

38.

Park JH, Cho BL, Kwon H, Prilutsky D, Yun JM, Choi HC, et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int. 2015;35(12):2537–46. https://doi.org/10.1111/liv.12909.CrossRefPubMed

39.

Peng XE, et al. Genetic Variants in PNPLA3 and Risk of Non-Alcoholic Fatty Liver Disease in a Han Chinese Population. Plos One. 2012;7(11):e50256.

40.

Rametta R, Ruscica M, Dongiovanni P, Macchi C, Fracanzani AL, Steffani L, et al. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-a independently of insulin resistance. Eur J Clin Investig. 2014;44(7):627–33. https://doi.org/10.1111/eci.12280.CrossRef

41.

Shang XR, Song JY, Liu FH, Ma J, Wang HJ. GWAS-identified common variants with nonalcoholic fatty liver disease in Chinese children. J Pediatr Gastroenterol Nutr. 2015;60(5):669–74. https://doi.org/10.1097/MPG.0000000000000662.CrossRefPubMed

42.

Uygun A, Ozturk K, Demirci H, Oztuna A, Eren F, Kozan S, et al. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. Eur J Gastroenterol Hepatol. 2017;29(4):441–7. https://doi.org/10.1097/MEG.0000000000000813.CrossRefPubMed

43.

Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, et al. The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol. 2012;12(1). https://doi.org/10.1186/1471-230X-12-111.

44.

Valenti L, al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the Patatin-like Phospholipase-3/Adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51(4):1209–17. https://doi.org/10.1002/hep.23622.CrossRefPubMed

45.

Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, et al. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol. 2016;51(8):967–73. https://doi.org/10.3109/00365521.2016.1161066.CrossRefPubMed

46.

Wang XL, et al. Additive effects of the risk alleles of PNPLA3 and TM6SF2 on non-alcoholic fatty liver disease (NAFLD) in a Chinese population. Front Genet. 2016;7. https://doi.org/10.3389/fgene.2016.00140.

47.

Yang HH, et al. A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elder Chinese: a population-based study. Medicine. 2018;97(13):e0272.

48.

Zhang RN, Zheng RD, Mi YQ, Zhou D, Shen F, Chen GY, et al. APOC3 rs2070666 is associated with the hepatic steatosis independently of PNPLA3 rs738409 in Chinese Han patients with nonalcoholic fatty liver diseases. Dig Dis Sci. 2016;61(8):2284–93. https://doi.org/10.1007/s10620-016-4120-7.CrossRefPubMed

49.

Liu ZT, Chen TC, Lu XX, Cheng J, Xie HY, Zhou L, et al. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients. World J Gastroenterol. 2015;21(34):10054–6. https://doi.org/10.3748/wjg.v21.i34.10054.CrossRefPubMedPubMedCentral

50.

Dai G, et al. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: a meta-analysis. Medicine (United States). 2019;98(7):e14324.

51.

Li J, et al. Effect of the patatin‐like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals. Pediatric Obesity. 2020;15(6):e12615.

52.

Honda Y, Yoneda M, Kessoku T, Ogawa Y, Tomeno W, Imajo K, et al. Characteristics of non-obese non-alcoholic fatty liver disease: effect of genetic and environmental factors. Hepatol Res. 2016;46(10):1011–8. https://doi.org/10.1111/hepr.12648.CrossRefPubMed

53.

Sood V, Khanna R, Rawat D, Sharma S, Alam S, Sarin SK. Study of family clustering and PNPLA3 gene polymorphism in pediatric non alcoholic fatty liver disease. Indian Pediatr. 2018;55(7):561–7. https://doi.org/10.1007/s13312-018-1297-1.CrossRefPubMed

54.

Chen LZ, Xin YN, Geng N, Jiang M, Zhang DD, Xuan SY. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World J Gastroenterol. 2015;21(3):794–802. https://doi.org/10.3748/wjg.v21.i3.794.CrossRefPubMedPubMedCentral

Title: Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis
Authors: Nader Salari
Niloufar Darvishi
Kamran Mansouri
Hooman Ghasemi
Melika Hosseinian-Far
Fateme Darvishi
Masoud Mohammadi
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Fatty Liver
Published in: BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-021-00789-4

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Clinical and demographic features among patients with type 1 diabetes mellitus in Henan, China

Bone mineral density predictors in long-standing type 1 and type 2 diabetes mellitus

Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study

Prevalence and determinants of diabetes and prediabetes in southwestern Iran: the Khuzestan comprehensive health study (KCHS)

Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial

Vitamin D and thyroid disorders: a systematic review and Meta-analysis of observational studies

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage